Premium
In vivo effect of interferon‐β 1a on interleukin‐12 and TGF‐β 1 cytokines in patients with relapsing–remitting multiple sclerosis
Author(s) -
Losy J.,
MichałowskaWender G.
Publication year - 2002
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2002.01209.x
Subject(s) - multiple sclerosis , in vivo , cytokine , medicine , beta (programming language) , interleukin , transforming growth factor beta , relapsing remitting , endocrinology , immunology , interleukin 4 , tgf beta signaling pathway , interleukin 17 , interferon beta 1a , transforming growth factor , interferon beta , biology , microbiology and biotechnology , programming language , computer science
We have studied in vivo effect of interferon‐β 1a (IFN‐β 1a) (6 MIU once weekly i.m.) on interleukin‐12 (IL‐12) and transforming growth factor‐β 1 (TGF‐β 1 ) serum levels during 6 months of therapy in group of 20 patients with relapsing–remitting multiple sclerosis (MS). IL‐12 and TGF‐β 1 concentrations were measured by enzyme linked immunoabsorbent assay (ELISA). There was a significant increase of IL‐12 levels in MS patients in comparison with control group, suggesting a role of this cytokine in immunity of MS. We have also found a significant increase of TGF‐β 1 levels after 6 months of therapy with IFN‐β 1a, however, there was no in vivo effect of the therapy on IL‐12 levels. The results suggest that IFN‐β 1a may exert its action through up‐ regulation and increase secretion of TGF‐β 1 .